Latanoprost - Latest Advances

The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Published: December 20, 2025

Comparison of Circadian Efficacy of Tafluprost Eye Drops (Taflotan Sine®) with Latanoprost Eye Drops (Xalatan®) in the Treatment of Open-Angle Glaucoma and Ocular Hypertension.

Journal: Journal of clinical medicine

Published: November 11, 2025

Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?

Journal: Advances in therapy

Published: October 23, 2025

Long-Term Outcome of Endothelial Keratoplasty Among Glaucoma Patients and the Risk of Prostaglandin Analogue (Latanoprost) Use on Graft Rejection.

Journal: Journal of clinical medicine

Published: October 02, 2025

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: September 16, 2025

Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial.

Journal: Journal of cataract and refractive surgery

Published: September 08, 2025

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: September 04, 2025

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation.

Journal: Journal of clinical medicine

Published: August 22, 2025

Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.

Journal: BMC ophthalmology

Published: August 13, 2025

Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.

Journal: Ophthalmology and therapy

Published: August 05, 2025

Impact of Two Different Antiglaucomatous Medications on Corneal Endothelium and Transparency: A Comparative Perspective.

Journal: Journal of current ophthalmology

Published: July 31, 2025

Very High Molecular Weight Hyaluronic Acid as an Enhanced Vehicle in Therapeutic Eye Drops: Application in a Novel Latanoprost Formulation for Glaucoma.

Journal: Bioengineering (Basel, Switzerland)

Published: July 23, 2025

Filters

The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys.

The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys.

Comparison of Circadian Efficacy of Tafluprost Eye Drops (Taflotan Sine®) with Latanoprost Eye Drops (Xalatan®) in the Treatment of Open-Angle Glaucoma and Ocular Hypertension.

Comparison of Circadian Efficacy of Tafluprost Eye Drops (Taflotan Sine®) with Latanoprost Eye Drops (Xalatan®) in the Treatment of Open-Angle Glaucoma and Ocular Hypertension.

Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?

Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?

Long-Term Outcome of Endothelial Keratoplasty Among Glaucoma Patients and the Risk of Prostaglandin Analogue (Latanoprost) Use on Graft Rejection.

Long-Term Outcome of Endothelial Keratoplasty Among Glaucoma Patients and the Risk of Prostaglandin Analogue (Latanoprost) Use on Graft Rejection.

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.

Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial.

Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial.

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain.

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain.

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation.

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation.

Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.

Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.

Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.

Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.

Impact of Two Different Antiglaucomatous Medications on Corneal Endothelium and Transparency: A Comparative Perspective.

Impact of Two Different Antiglaucomatous Medications on Corneal Endothelium and Transparency: A Comparative Perspective.

Very High Molecular Weight Hyaluronic Acid as an Enhanced Vehicle in Therapeutic Eye Drops: Application in a Novel Latanoprost Formulation for Glaucoma.

Very High Molecular Weight Hyaluronic Acid as an Enhanced Vehicle in Therapeutic Eye Drops: Application in a Novel Latanoprost Formulation for Glaucoma.